Aptamer-based therapeutics: New approaches to combat human viral diseases

Pharmaceuticals

Volumn 6, Issue 12, 2013, Pages 1507-1542

  Shum, Ka To ^a   Zhou, Jiehua ^a   Rossi, John J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Aptamers; HIV 1; RNA nanotechnology; SELEX; Virus

Indexed keywords

2' FLUORO MODIFIED RNA; 2' METHYL MODIFIED DNA; 37 NT; ANTIVIRUS AGENT; APTAMER; B 40; BOCEPREVIR; DNA; DP 6 22; ELVITEGRAVIR; G 6 16; GUANINE QUADRUPLEX; J 58; M 302; N 50 20; N 70 13; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; ODN 112; PF 1; PSEUDOKNOT; R 122; RNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; RT 1 T 49; RT 1T 49; RU 25 80; T 30695; THIOLATED DNA APTAMER; UCLA1; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; BINDING AFFINITY; COMBINATORIAL CHEMISTRY; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG RESEARCH; ENZYME ACTIVITY; ENZYME INHIBITION; GENETIC TRANSFECTION; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; IC 50; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS; INTERNAL RIBOSOME ENTRY SITE; NONHUMAN; PAPILLOMA VIRUS; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN PURIFICATION; PROTEIN STRUCTURE; RABIES; RABIES VIRUS; REVIEW; SEVERE ACUTE RESPIRATORY SYNDROME; VIRUS INFECTION; VIRUS INHIBITION;

EID: 84888342497     PISSN: None     EISSN: 14248247     Source Type: Journal    
DOI: 10.3390/ph6121507     Document Type: Review

References (213)

1. Haasnoot, J.; Berkhout, B. Nucleic acids-based therapeutics in the battle against pathogenic viruses. Handb. Exp. Pharmacol. 2009, 189, 243-263.
2. Mescalchin, A.; Restle, T. Oligomeric nucleic acids as antivirals. Molecules 2011, 16, 1271-1296.
3. Alter, G.; Heckerman, D.; Schneidewind, A.; Fadda, L.; Kadie, C. M.; Carlson, J. M.; Oniangue-Ndza, C.; Martin, M.; Li, B.; Khakoo, S. I.; et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011, 476, 96-100.
4. Ding, Q.; Cao, X.; Lu, J.; Huang, B.; Liu, Y. J.; Kato, N.; Shu, H. B.; Zhong, J. Hepatitis C virus NS4B blocks the interaction of STING and TBK1 to evade host innate immunity. J. Hepatol. 2013, 59, 52-58.
5. Arts, E. J.; Hazuda, D. J. HIV-1 antiretroviral drug therapy. Cold Spring Harb. Perspect. Med. 2012, 2, a007161.
6. Gopinath, S. C. Antiviral aptamers. Arch. Virol. 2007, 152, 2137-2157.
7. Jordheim, L. P.; Durantel, D.; Zoulim, F.; Dumontet, C. Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases. Nat. Rev. Drug Discov. 2013, 12, 447-464.
8. Jones, M.; Nunez, M. Liver toxicity of antiretroviral drugs. Semin. Liver Dis. 2012, 32, 167-176.
9. Preston, B. D.; Poiesz, B. J.; Loeb, L. A. Fidelity of HIV-1 reverse transcriptase. Science 1988, 242, 1168-1171.
10. Brown, A. J.; Cleland, A. Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS 1996, 10, 1067-1073.
11. Kwong, A. D.; Rao, B. G.; Jeang, K. T. Viral and cellular RNA helicases as antiviral targets. Nat. Rev. Drug Discov. 2005, 4, 845-853.
12. Kuritzkes, D. R. Drug resistance in HIV-1. Curr. Opin. Virol. 2011, 1, 582-589.
13. Garcia-Lerma, J. G.; Nidtha, S.; Blumoff, K.; Weinstock, H.; Heneine, W. Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug-naive persons. Proc. Natl. Acad. Sci. USA 2001, 98, 13907-13912.
14. Schmitz, S. H.; Scheding, S.; Voliotis, D.; Rasokat, H.; Diehl, V.; Schrappe, M. Side effects of AZT prophylaxis after occupational exposure to HIV-infected blood. Ann. Hematol. 1994, 69, 135-138.
15. Kuehl, A. K.; Noormohamed, S. E. Recombinant erythropoietin for zidovudine-induced anemia in AIDS. Ann. Pharmacother. 1995, 29, 778-779.
16. Rachlis, A.; Fanning, M. M. Zidovudine toxicity. Clinical features and management. Drug Saf. 1993, 8, 312-320.
17. Ellington, A. D.; Szostak, J. W. In vitro selection of RNA molecules that bind specific ligands. Nature 1990, 346, 818-822.
18. Tuerk, C.; MacDougal-Waugh, S. In vitro evolution of functional nucleic acids: High-affinity RNA ligands of HIV-1 proteins. Gene 1993, 137, 33-39.
19. Hernandez, L. I.; Flenker, K. S.; Hernandez, F. J.; Klingelhutz, A. J.; McNamara, J. O.; Giangrande, P. H. Methods for evaluating cell-specific, cell-internalizing RNA aptamers. Pharmaceuticals 2013, 6, 295-319.
20. Zhou, J.; Li, H.; Zhang, J.; Piotr, S.; Rossi, J. Development of cell-type specific anti-HIV gp120 aptamers for siRNA delivery. J. Vis. Exp. 2011, 52, 357-368.
21. Liu, J.; You, M.; Pu, Y.; Liu, H.; Ye, M.; Tan, W. Recent developments in protein and cell-targeted aptamer selection and applications. Curr. Med. Chem. 2011, 18, 4117-4125.
22. McNamara, J. O., 2nd; Andrechek, E. R.; Wang, Y.; Viles, K. D.; Rempel, R. E.; Gilboa, E.; Sullenger, B. A.; Giangrande, P. H. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat. Biotechnol. 2006, 24, 1005-1015.
23. Zhou, J.; Rossi, J. J. Aptamer-targeted RNAi for HIV-1 therapy. Methods Mol. Biol. 2011, 721, 355-371.
24. Zhou, J.; Rossi, J. J. Aptamer-targeted cell-specific RNA interference. Silence 2010, 1, 4.
25. Tucker, W. O.; Shum, K. T.; Tanner, J. A. G-quadruplex DNA aptamers and their ligands: Structure, function and application. Curr. Pharm. Des. 2012, 18, 2014-2026.
26. Nimjee, S. M.; Rusconi, C. P.; Sullenger, B. A. Aptamers: An emerging class of therapeutics. Annu. Rev. Med. 2005, 56, 555-583.
27. Ng, E. W.; Shima, D. T.; Calias, P.; Cunningham, E. T., Jr.; Guyer, D. R.; Adamis, A. P. Pegaptanib, a targeted anti-VEGF aptamer for ocular vascular disease. Nat. Rev. Drug Discov. 2006, 5, 123-132.
28. Doggrell, S. A. Pegaptanib: The first antiangiogenic agent approved for neovascular macular degeneration. Expert Opin. Pharmacother. 2005, 6, 1421-1423.
29. Sundaram, P.; Kurniawan, H.; Byrne, M. E.; Wower, J. Therapeutic RNA aptamers in clinical trials. Eur. J. Pharm. Sci. 2013, 48, 259-271.
30. Burnett, J. C.; Rossi, J. J. RNA-based therapeutics: Current progress and future prospects. Chem. Biol. 2012, 19, 60-71.
31. Mongelard, F.; Bouvet, P. AS-1411, a guanosine-rich oligonucleotide aptamer targeting nucleolin for the potential treatment of cancer, including acute myeloid leukemia. Curr. Opin. Mol. Ther. 2010, 12, 107-114.
32. Gilbert, J. C.; DeFeo-Fraulini, T.; Hutabarat, R. M.; Horvath, C. J.; Merlino, P. G.; Marsh, H. N.; Healy, J. M.; Boufakhreddine, S.; Holohan, T. V.; Schaub, R. G. First-in-human evaluation of anti von Willebrand factor therapeutic aptamer ARC1779 in healthy volunteers. Circulation 2007, 116, 2678-2686.
33. Vinores, S. A. Pegaptanib in the treatment of wet, age-related macular degeneration. Int. J. Nanomed. 2006, 1, 263-268.
34. Zhou, J.; Rossi, J. J. Therapeutic potential of aptamer-siRNA conjugates for treatment of HIV-1. BioDrugs 2012, 26, 393-400.
35. Zhou, J.; Rossi, J. J. Progress in RNAi-based antiviral therapeutics. Methods Mol. Biol. 2011, 721, 67-75.
36. Zhou, J.; Rossi, J. J. Cell-specific aptamer-mediated targeted drug delivery. Oligonucleotides 2011, 21, 1-10.
37. Zhou, J.; Rossi, J. J. Bivalent aptamers deliver the punch. Chem. Biol. 2008, 15, 644-645.
38. Kanwar, J. R.; Roy, K.; Kanwar, R. K. Chimeric aptamers in cancer cell-targeted drug delivery. Crit. Rev. Biochem. Mol. Biol. 2011, 46, 459-477.
39. Khati, M. The future of aptamers in medicine. J. Clin. Pathol. 2010, 63, 480-487.
40. Cheung, Y. W.; Kwok, J.; Law, A. W.; Watt, R. M.; Kotaka, M.; Tanner, J. A. Structural basis for discriminatory recognition of Plasmodium lactate dehydrogenase by a DNA aptamer. Proc. Natl. Acad. Sci. USA 2013, 110, 15967-15972.
41. Bunka, D. H.; Stockley, P. G. Aptamers come of age-at last. Nat. Rev. Microbiol. 2006, 4, 588-596.
42. Tuerk, C.; MacDougal, S.; Gold, L. RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc. Natl. Acad. Sci. USA 1992, 89, 6988-6992.
43. Jaeger, J.; Restle, T.; Steitz, T. A. The structure of HIV-1 reverse transcriptase complexed with an RNA pseudoknot inhibitor. EMBO J. 1998, 17, 4535-4542.
44. Guo, P. The emerging field of RNA nanotechnology. Nat. Nanotechnol. 2010, 5, 833-842.
45. Guo, P.; Haque, F.; Hallahan, B.; Reif, R.; Li, H. Uniqueness, advantages, challenges, solutions, and perspectives in therapeutics applying RNA nanotechnology. Nucleic Acid Ther. 2012, 22, 226-245.
46. Shukla, G. C.; Haque, F.; Tor, Y.; Wilhelmsson, L. M.; Toulme, J. J.; Isambert, H.; Guo, P.; Rossi, J. J.; Tenenbaum, S. A.; Shapiro, B. A. A boost for the emerging field of RNA nanotechnology. ACS Nano 2011, 5, 3405-3418.
47. Tarapore, P.; Shu, Y.; Guo, P.; Ho, S. M. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. Mol. Ther. 2011, 19, 386-394.
48. Shu, Y.; Cinier, M.; Shu, D.; Guo, P. Assembly of multifunctional phi29 pRNA nanoparticles for specific delivery of siRNA and other therapeutics to targeted cells. Methods 2011, 54, 204-214.
49. Shu, Y.; Haque, F.; Shu, D.; Li, W.; Zhu, Z.; Kotb, M.; Lyubchenko, Y.; Guo, P. Fabrication of 14 different RNA nanoparticles for specific tumor targeting without accumulation in normal organs. RNA 2013, 19, 767-777.
50. Neff, C. P.; Zhou, J.; Remling, L.; Kuruvilla, J.; Zhang, J.; Li, H.; Smith, D. D.; Swiderski, P.; Rossi, J. J.; Akkina, R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med. 2011, 3, 66ra6.
51. Bai, J.; Banda, N.; Lee, N. S.; Rossi, J.; Akkina, R. RNA-based anti-HIV-1 gene therapeutic constructs in SCID-hu mouse model. Mol. Ther. 2002, 6, 770-782.
52. Ahmad, K. M.; Xiao, Y.; Soh, H. T. Selection is more intelligent than design: Improving the affinity of a bivalent ligand through directed evolution. Nucleic Acids Res. 2012, 40, 11777-11783.
53. Ye, M.; Hu, J.; Peng, M.; Liu, J.; Liu, H.; Zhao, X.; Tan, W. Generating aptamers by cell-SELEX for applications in molecular medicine. Int. J. Mol. Sci. 2012, 13, 3341-3353.
54. Dua, P.; Kim, S.; Lee, D. K. Nucleic acid aptamers targeting cell-surface proteins. Methods 2011, 54, 215-225.
55. Tang, Z.; Parekh, P.; Turner, P.; Moyer, R. W.; Tan, W. Generating aptamers for recognition of virus-infected cells. Clin. Chem. 2009, 55, 813-822.
56. Richman, D. D.; Margolis, D. M.; Delaney, M.; Greene, W. C.; Hazuda, D.; Pomerantz, R. J. The challenge of finding a cure for HIV infection. Science 2009, 323, 1304-1307.
57. Joshi, P. J.; Fisher, T. S.; Prasad, V. R. Anti-HIV inhibitors based on nucleic acids: Emergence of aptamers as potent antivirals. Curr. Drug Targets Infect. Disord. 2003, 3, 383-400.
58. Scherer, L.; Rossi, J. J.; Weinberg, M. S. Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther. 2007, 14, 1057-1064.
59. Held, D. M.; Kissel, J. D.; Patterson, J. T.; Nickens, D. G.; Burke, D. H. HIV-1 inactivation by nucleic acid aptamers. Front. Biosci. 2006, 11, 89-112.
60. Jager, J.; Pata, J. D. Getting a grip: Polymerases and their substrate complexes. Curr. Opin. Struct. Biol. 1999, 9, 21-28.
61. De Clercq, E. Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS). J. Med. Chem. 1986, 29, 1561-1569.
62. De Clercq, E. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 1999, 54, 26-45.
63. Kensch, O.; Connolly, B. A.; Steinhoff, H. J.; McGregor, A.; Goody, R. S.; Restle, T. HIV-1 reverse transcriptase-pseudoknot RNA aptamer interaction has a binding affinity in the low picomolar range coupled with high specificity. J. Biol. Chem. 2000, 275, 18271-18278.
64. Chaloin, L.; Lehmann, M. J.; Sczakiel, G.; Restle, T. Endogenous expression of a high-affinity pseudoknot RNA aptamer suppresses replication of HIV-1. Nucleic Acids Res. 2002, 30, 4001-4008.
65. Li, N.; Wang, Y.; Pothukuchy, A.; Syrett, A.; Husain, N.; Gopalakrisha, S.; Kosaraju, P.; Ellington, A. D. Aptamers that recognize drug-resistant HIV-1 reverse transcriptase. Nucleic Acids Res. 2008, 36, 6739-6751.
66. Andreola, M. L.; Pileur, F.; Calmels, C.; Ventura, M.; Tarrago-Litvak, L.; Toulme, J. J.; Litvak, S. DNA aptamers selected against the HIV-1 RNase H display in vitro antiviral activity. Biochemistry 2001, 40, 10087-10094.
67. Somasunderam, A.; Ferguson, M. R.; Rojo, D. R.; Thiviyanathan, V.; Li, X.; O'Brien, W. A.; Gorenstein, D. G. Combinatorial selection, inhibition, and antiviral activity of DNA thioaptamers targeting the RNase H domain of HIV-1 reverse transcriptase. Biochemistry 2005, 44, 10388-10395.
68. DeStefano, J. J.; Nair, G. R. Novel aptamer inhibitors of human immunodeficiency virus reverse transcriptase. Oligonucleotides 2008, 18, 133-144.
69. Schneider, D. J.; Feigon, J.; Hostomsky, Z.; Gold, L. High-affinity ssDNA inhibitors of the reverse transcriptase of type 1 human immunodeficiency virus. Biochemistry 1995, 34, 9599-9610.
70. Kissel, J. D.; Held, D. M.; Hardy, R. W.; Burke, D. H. Single-stranded DNA aptamer RT1t49 inhibits RT polymerase and RNase H functions of HIV type 1, HIV type 2, and SIVCPZ RTs. AIDS Res. Hum. Retroviruses 2007, 23, 699-708.
71. Lai, Y. T.; DeStefano, J. J. DNA aptamers to human immunodeficiency virus reverse transcriptase selected by a primer-free SELEX method: Characterization and comparison with other aptamers. Nucleic Acid Ther. 2012, 22, 162-176.
72. Whatley, A. S.; Ditzler, M. A.; Lange, M. J.; Biondi, E.; Sawyer, A. W.; Chang, J. L.; Franken, J. D.; Burke, D. H. Potent Inhibition of HIV-1 Reverse Transcriptase and Replication by Nonpseudoknot, "UCAA-motif" RNA Aptamers. Mol. Ther. Nucleic Acids 2013, 2, e71.
73. Ditzler, M. A.; Lange, M. J.; Bose, D.; Bottoms, C. A.; Virkler, K. F.; Sawyer, A. W.; Whatley, A. S.; Spollen, W.; Givan, S. A.; Burke, D. H. High-throughput sequence analysis reveals structural diversity and improved potency among RNA inhibitors of HIV reverse transcriptase. Nucleic Acids Res. 2013, 41, 1873-1884.
74. De Soultrait, V. R.; Lozach, P. Y.; Altmeyer, R.; Tarrago-Litvak, L.; Litvak, S.; Andreola, M. L. DNA aptamers derived from HIV-1 RNase H inhibitors are strong anti-integrase agents. J. Mol. Biol. 2002, 324, 195-203.
75. Faure-Perraud, A.; Metifiot, M.; Reigadas, S.; Recordon-Pinson, P.; Parissi, V.; Ventura, M.; Andreola, M. L. The guanine-quadruplex aptamer 93del inhibits HIV-1 replication ex vivo by interfering with viral entry, reverse transcription and integration. Antivir. Ther. 2011, 16, 383-394.
76. Jing, N.; Hogan, M. E. Structure-activity of tetrad-forming oligonucleotides as a potent anti-HIV therapeutic drug. J. Biol. Chem. 1998, 273, 34992-34999.
77. Ramalingam, D.; Duclair, S.; Datta, S. A.; Ellington, A.; Rein, A.; Prasad, V. R. RNA aptamers directed to human immunodeficiency virus type 1 Gag polyprotein bind to the matrix and nucleocapsid domains and inhibit virus production. J. Virol. 2011, 85, 305-314.
78. Kim, S. J.; Kim, M. Y.; Lee, J. H.; You, J. C.; Jeong, S. Selection and stabilization of the RNA aptamers against the human immunodeficiency virus type-1 nucleocapsid protein. Biochem. Biophys. Res. Commun. 2002, 291, 925-931.
79. Kim, M. Y.; Jeong, S. RNA aptamers that bind the nucleocapsid protein contain pseudoknots. Mol. Cells 2003, 16, 413-417.
80. Sayer, N.; Ibrahim, J.; Turner, K.; Tahiri-Alaoui, A.; James, W. Structural characterization of a 2'F-RNA aptamer that binds a HIV-1 SU glycoprotein, gp120. Biochem. Biophys. Res. Commun. 2002, 293, 924-931.
81. Mufhandu, H. T.; Gray, E. S.; Madiga, M. C.; Tumba, N.; Alexandre, K. B.; Khoza, T.; Wibmer, C. K.; Moore, P. L.; Morris, L.; Khati, M. UCLA1, a synthetic derivative of a gp120 RNA aptamer, inhibits entry of human immunodeficiency virus type 1 subtype C. J. Virol. 2012, 86, 4989-4999.
82. Zhou, J.; Neff, C. P.; Liu, X.; Zhang, J.; Li, H.; Smith, D. D.; Swiderski, P.; Aboellail, T.; Huang, Y.; Du, Q.; et al. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol. Ther. 2011, 19, 2228-2238.
83. Zhou, J.; Swiderski, P.; Li, H.; Zhang, J.; Neff, C. P.; Akkina, R.; Rossi, J. J. Selection, characterization and application of new RNA HIV gp 120 aptamers for facile delivery of Dicer substrate siRNAs into HIV infected cells. Nucleic Acids Res. 2009, 37, 3094-3109.
84. Yamamoto, R.; Katahira, M.; Nishikawa, S.; Baba, T.; Taira, K.; Kumar, P. K. A novel RNA motif that binds efficiently and specifically to the Ttat protein of HIV and inhibits the trans-activation by Tat of transcription in vitro and in vivo. Genes Cells 2000, 5, 371-388.
85. Jensen, K. B.; Green, L.; MacDougal-Waugh, S.; Tuerk, C. Characterization of an in vitro-selected RNA ligand to the HIV-1 Rev protein. J. Mol. Biol. 1994, 235, 237-247.
86. Boiziau, C.; Dausse, E.; Yurchenko, L.; Toulme, J. J. DNA aptamers selected against the HIV-1 trans-activation-responsive RNA element form RNA-DNA kissing complexes. J. Biol. Chem. 1999, 274, 12730-12737.
87. Duconge, F.; Toulme, J. J. In vitro selection identifies key determinants for loop-loop interactions: RNA aptamers selective for the TAR RNA element of HIV-1. RNA 1999, 5, 1605-1614.
88. Watrin, M.; von Pelchrzim, F.; Dausse, E.; Schroeder, R.; Toulme, J. J. In vitro selection of RNA aptamers derived from a genomic human library against the TAR RNA element of HIV-1. Biochemistry 2009, 48, 6278-6284.
89. Sekkai, D.; Dausse, E.; di Primo, C.; Darfeuille, F.; Boiziau, C.; Toulme, J. J. In vitro selection of DNA aptamers against the HIV-1 TAR RNA hairpin. Antisense Nucleic Acid Drug Dev. 2002, 12, 265-274.
90. Kumar, P. K.; Machida, K.; Urvil, P. T.; Kakiuchi, N.; Vishnuvardhan, D.; Shimotohno, K.; Taira, K.; Nishikawa, S. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 1997, 237, 270-282.
91. Fukuda, K.; Vishnuvardhan, D.; Sekiya, S.; Hwang, J.; Kakiuchi, N.; Taira, K.; Shimotohno, K.; Kumar, P. K.; Nishikawa, S. Isolation and characterization of RNA aptamers specific for the hepatitis C virus nonstructural protein 3 protease. Eur. J. Biochem. 2000, 267, 3685-3694.
92. Nishikawa, F.; Funaji, K.; Fukuda, K.; Nishikawa, S. In vitro selection of RNA aptamers against the HCV NS3 helicase domain. Oligonucleotides 2004, 14, 114-129.
93. Biroccio, A.; Hamm, J.; Incitti, I.; de Francesco, R.; Tomei, L. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 2002, 76, 3688-3696.
94. Bellecave, P.; Cazenave, C.; Rumi, J.; Staedel, C.; Cosnefroy, O.; Andreola, M. L.; Ventura, M.; Tarrago-Litvak, L.; Astier-Gin, T. Inhibition of hepatitis C virus (HCV) RNA polymerase by DNA aptamers: Mechanism of inhibition of in vitro RNA synthesis and effect on HCV-infected cells. Antimicrob. Agents Chemother. 2008, 52, 2097-2110.
95. Lee, C. H.; Lee, Y. J.; Kim, J. H.; Lim, J. H.; Kim, J. H.; Han, W.; Lee, S. H.; Noh, G. J.; Lee, S. W. Inhibition of hepatitis C virus (HCV) replication by specific RNA aptamers against HCV NS5B RNA replicase. J. Virol. 2013, 87, 7064-7074.
96. Marton, S.; Romero-Lopez, C.; Berzal-Herranz, A. RNA aptamer-mediated interference of HCV replication by targeting the CRE-5BSL3. 2 domain. J. Viral Hepat. 2013, 20, 103-112.
97. Kikuchi, K.; Umehara, T.; Fukuda, K.; Hwang, J.; Kuno, A.; Hasegawa, T.; Nishikawa, S. RNA aptamers targeted to domain II of hepatitis C virus IRES that bind to its apical loop region. J. Biochem. 2003, 133, 263-270.
98. Kikuchi, K.; Umehara, T.; Fukuda, K.; Kuno, A.; Hasegawa, T.; Nishikawa, S. A hepatitis C virus (HCV) internal ribosome entry site (IRES) domain III-IV-targeted aptamer inhibits translation by binding to an apical loop of domain IIId. Nucleic Acids Res. 2005, 33, 683-692.
99. Romero-Lopez, C.; Barroso-delJesus, A.; Puerta-Fernandez, E.; Berzal-Herranz, A. Interfering with hepatitis C virus IRES activity using RNA molecules identified by a novel in vitro selection method. Biol. Chem. 2005, 386, 183-190.
100. Romero-Lopez, C.; Diaz-Gonzalez, R.; Barroso-delJesus, A.; Berzal-Herranz, A. Inhibition of hepatitis C virus replication and internal ribosome entry site-dependent translation by an RNA molecule. J. Gen. Virol. 2009, 90, 1659-1669.
101. Liu, J.; Yang, Y.; Hu, B.; Ma, Z. Y.; Huang, H. P.; Yu, Y.; Liu, S. P.; Lu, M. J.; Yang, D. L. Development of HBsAg-binding aptamers that bind HepG2. 2. 15 cells via HBV surface antigen. Virol. Sin. 2010, 25, 27-35.
102. Feng, H.; Beck, J.; Nassal, M.; Hu, K. H. A SELEX-screened aptamer of human hepatitis B virus RNA encapsidation signal suppresses viral replication. PLoS One 2011, 6, e27862.
103. Shum, K. T.; Tanner, J. A. Differential inhibitory activities and stabilisation of DNA aptamers against the SARS coronavirus helicase. ChemBioChem 2008, 9, 3037-3045.
104. Jang, K. J.; Lee, N. R.; Yeo, W. S.; Jeong, Y. J.; Kim, D. E. Isolation of inhibitory RNA aptamers against severe acute respiratory syndrome (SARS) coronavirus NTPase/Helicase. Biochem. Biophys. Res. Commun. 2008, 366, 738-744.
105. Jeon, S. H.; Kayhan, B.; Ben-Yedidia, T.; Arnon, R. A DNA aptamer prevents influenza infection by blocking the receptor binding region of the viral hemagglutinin. J. Biol. Chem. 2004, 279, 48410-48419.
106. Cheng, C.; Dong, J.; Yao, L.; Chen, A.; Jia, R.; Huan, L.; Guo, J.; Shu, Y.; Zhang, Z. Potent inhibition of human influenza H5N1 virus by oligonucleotides derived by SELEX. Biochem. Biophys. Res. Commun. 2008, 366, 670-674.
107. Gopinath, S. C.; Misono, T. S.; Kawasaki, K.; Mizuno, T.; Imai, M.; Odagiri, T.; Kumar, P. K. An RNA aptamer that distinguishes between closely related human influenza viruses and inhibits haemagglutinin-mediated membrane fusion. J. Gen. Virol. 2006, 87, 479-487.
108. Misono, T. S.; Kumar, P. K. Selection of RNA aptamers against human influenza virus hemagglutinin using surface plasmon resonance. Anal. Biochem. 2005, 342, 312-317.
109. Wongphatcharachai, M.; Wang, P.; Enomoto, S.; Webby, R. J.; Gramer, M. R.; Amonsin, A.; Sreevatsan, S. Neutralizing DNA aptamers against swine influenza H3N2 viruses. J. Clin. Microbiol. 2013, 51, 46-54.
110. Choi, S. K.; Lee, C.; Lee, K. S.; Choe, S. Y.; Mo, I. P.; Seong, R. H.; Hong, S.; Jeon, S. H. DNA aptamers against the receptor binding region of hemagglutinin prevent avian influenza viral infection. Mol. Cells 2011, 32, 527-533.
111. Park, S. Y.; Kim, S.; Yoon, H.; Kim, K. B.; Kalme, S. S.; Oh, S.; Song, C. S.; Kim, D. E. Selection of an antiviral RNA aptamer against hemagglutinin of the subtype H5 avian influenza virus. Nucleic Acid Ther. 2011, 21, 395-402.
112. Gopinath, S. C.; Sakamaki, Y.; Kawasaki, K.; Kumar, P. K. An efficient RNA aptamer against human influenza B virus hemagglutinin. J. Biochem. 2006, 139, 837-846.
113. Liang, H. R.; Hu, G. Q.; Zhang, T.; Yang, Y. J.; Zhao, L. L.; Qi, Y. L.; Wang, H. L.; Gao, Y. W.; Yang, S. T.; Xia, X. Z. Isolation of ssDNA aptamers that inhibit rabies virus. Int. Immunopharmacol. 2012, 14, 341-347.
114. Liang, H. R.; Liu, Q.; Zheng, X. X.; Gai, W. W.; Xue, X. H.; Hu, G. Q.; Wu, H. X.; Wang, H. L.; Yang, S. T.; Xia, X. Z. Aptamers targeting rabies virus-infected cells inhibit viral replication both in vitro and in vivo. Virus Res. 2013, 173, 398-403.
115. Toscano-Garibay, J. D.; Benitez-Hess, M. L.; Alvarez-Salas, L. M. Isolation and characterization of an RNA aptamer for the HPV-16 E7 oncoprotein. Arch. Med. Res. 2011, 42, 88-96.
116. Graham, J. C.; Zarbl, H. Use of cell-SELEX to generate DNA aptamers as molecular probes of HPV-associated cervical cancer cells. PLoS One 2012, 7, e36103.
117. Nicol, C.; Cesur, O.; Forrest, S.; Belyaeva, T. A.; Bunka, D. H.; Blair, G. E.; Stonehouse, N. J. An RNA aptamer provides a novel approach for the induction of apoptosis by targeting the HPV16 E7 oncoprotein. PLoS One 2013, 8, e64781.
118. Nicol, C.; Bunka, D. H.; Blair, G. E.; Stonehouse, N. J. Effects of single nucleotide changes on the binding and activity of RNA aptamers to human papillomavirus 16 E7 oncoprotein. Biochem. Biophys. Res. Commun. 2011, 405, 417-421.
119. Gopinath, S. C.; Hayashi, K.; Kumar, P. K. Aptamer that binds to the gD protein of herpes simplex virus 1 and efficiently inhibits viral entry. J. Virol. 2012, 86, 6732-6744.
120. Moore, M. D.; Bunka, D. H.; Forzan, M.; Spear, P. G.; Stockley, P. G.; McGowan, I.; James, W. Generation of neutralizing aptamers against herpes simplex virus type 2: Potential components of multivalent microbicides. J. Gen. Virol. 2011, 92, 1493-1499.
121. Nickens, D. G.; Patterson, J. T.; Burke, D. H. Inhibition of HIV-1 reverse transcriptase by RNA aptamers in Escherichia coli. RNA 2003, 9, 1029-1033.
122. Joshi, P.; Prasad, V. R. Potent inhibition of human immunodeficiency virus type 1 replication by template analog reverse transcriptase inhibitors derived by SELEX (systematic evolution of ligands by exponential enrichment). J. Virol. 2002, 76, 6545-6557.
123. Lange, M. J.; Sharma, T. K.; Whatley, A. S.; Landon, L. A.; Tempesta, M. A.; Johnson, M. C.; Burke, D. H. Robust suppression of HIV replication by intracellularly expressed reverse transcriptase aptamers is independent of ribozyme processing. Mol. Ther. 2012, 20, 2304-2314.
124. Asante-Appiah, E.; Skalka, A. M. Molecular mechanisms in retrovirus DNA integration. Antiviral Res. 1997, 36, 139-156.
125. Li, T.; Shi, L.; Wang, E.; Dong, S. Multifunctional G-quadruplex aptamers and their application to protein detection. Chemistry 2009, 15, 1036-1042.
126. Phan, A. T.; Kuryavyi, V.; Ma, J. B.; Faure, A.; Andreola, M. L.; Patel, D. J. An interlocked dimeric parallel-stranded DNA quadruplex: A potent inhibitor of HIV-1 integrase. Proc. Natl. Acad. Sci. USA 2005, 102, 634-639.
127. Chou, S. H.; Chin, K. H.; Wang, A. H. DNA aptamers as potential anti-HIV agents. Trends Biochem. Sci. 2005, 30, 231-234.
128. Mazumder, A.; Neamati, N.; Ojwang, J. O.; Sunder, S.; Rando, R. F.; Pommier, Y. Inhibition of the human immunodeficiency virus type 1 integrase by guanosine quartet structures. Biochemistry 1996, 35, 13762-13771.
129. Magbanua, E.; Zivkovic, T.; Hansen, B.; Beschorner, N.; Meyer, C.; Lorenzen, I.; Grotzinger, J.; Hauber, J.; Torda, A. E.; Mayer, G.; et al. d(GGGT) 4 and r(GGGU) 4 are both HIV-1 inhibitors and interleukin-6 receptor aptamers. RNA Biol. 2013, 10, 216-227.
130. Gheysen, D.; Jacobs, E.; de Foresta, F.; Thiriart, C.; Francotte, M.; Thines, D.; de Wilde, M. Assembly and release of HIV-1 precursor Pr55gag virus-like particles from recombinant baculovirus-infected insect cells. Cell 1989, 59, 103-112.
131. Wills, J. W.; Craven, R. C. Form, function, and use of retroviral gag proteins. AIDS 1991, 5, 639-654.
132. Demirov, D. G.; Freed, E. O. Retrovirus budding. Virus Res. 2004, 106, 87-102.
133. Rein, A.; Henderson, L. E.; Levin, J. G. Nucleic-acid-chaperone activity of retroviral nucleocapsid proteins: Significance for viral replication. Trends Biochem. Sci. 1998, 23, 297-301.
134. De Guzman, R. N.; Wu, Z. R.; Stalling, C. C.; Pappalardo, L.; Borer, P. N.; Summers, M. F. Structure of the HIV-1 nucleocapsid protein bound to the SL3 psi-RNA recognition element. Science 1998, 279, 384-388.
135. Kim, M. Y.; Jeong, S. Inhibition of the functions of the nucleocapsid protein of human immunodeficiency virus-1 by an RNA aptamer. Biochem. Biophys. Res. Commun. 2004, 320, 1181-1186.
136. Kwong, P. D.; Wyatt, R.; Robinson, J.; Sweet, R. W.; Sodroski, J.; Hendrickson, W. A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393, 648-659.
137. Sattentau, Q. J.; Moore, J. P. The role of CD4 in HIV binding and entry. Philos. Trans. R. Soc. Lond. B Biol. Sci. 1993, 342, 59-66.
138. Ugolini, S.; Mondor, I.; Sattentau, Q. J. HIV-1 attachment: Another look. Trends Microbiol. 1999, 7, 144-149.
139. Khati, M.; Schuman, M.; Ibrahim, J.; Sattentau, Q.; Gordon, S.; James, W. Neutralization of infectivity of diverse R5 clinical isolates of human immunodeficiency virus type 1 by gp120-binding 2'F-RNA aptamers. J. Virol. 2003, 77, 12692-12698.
140. Dey, A. K.; Griffiths, C.; Lea, S. M.; James, W. Structural characterization of an anti-gp120 RNA aptamer that neutralizes R5 strains of HIV-1. RNA 2005, 11, 873-884.
141. Dey, A. K.; Khati, M.; Tang, M.; Wyatt, R.; Lea, S. M.; James, W. An aptamer that neutralizes R5 strains of human immunodeficiency virus type 1 blocks gp120-CCR5 interaction. J. Virol. 2005, 79, 13806-13810.
142. Cohen, C.; Forzan, M.; Sproat, B.; Pantophlet, R.; McGowan, I.; Burton, D.; James, W. An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site. Virology 2008, 381, 46-54.
143. Zhou, J.; Li, H.; Li, S.; Zaia, J.; Rossi, J. J. Novel dual inhibitory function aptamer-siRNA delivery system for HIV-1 therapy. Mol. Ther. 2008, 16, 1481-1489.
144. Zhou, J.; Neff, C. P.; Swiderski, P.; Li, H.; Smith, D. D.; Aboellail, T.; Remling-Mulder, L.; Akkina, R.; Rossi, J. J. Functional in vivo delivery of multiplexed anti-HIV-1 siRNAs via a chemically synthesized aptamer with a sticky bridge. Mol. Ther. 2013, 21, 192-200.
145. Arya, S. K.; Guo, C.; Josephs, S. F.; Wong-Staal, F. Trans-activator gene of human T-lymphotropic virus type III (HTLV-III). Science 1985, 229, 69-73.
146. Berkhout, B.; Silverman, R. H.; Jeang, K. T. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 1989, 59, 273-282.
147. Ensoli, B.; Barillari, G.; Salahuddin, S. Z.; Gallo, R. C.; Wong-Staal, F. Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients. Nature 1990, 345, 84-86.
148. Cullen, B. R.; Greene, W. C. Regulatory pathways governing HIV-1 replication. Cell 1989, 58, 423-426.
149. Rosen, C. A.; Pavlakis, G. N. Tat and Rev: Positive regulators of HIV gene expression. AIDS 1990, 4, 499-509.
150. Kjems, J.; Frankel, A. D.; Sharp, P. A. Specific regulation of mRNA splicing in vitro by a peptide from HIV-1 Rev. Cell 1991, 67, 169-178.
151. Konopka, K.; Lee, N. S.; Rossi, J.; Duzgunes, N. Rev-binding aptamer and CMV promoter act as decoys to inhibit HIV replication. Gene 2000, 255, 235-244.
152. Gait, M. J.; Karn, J. RNA recognition by the human immunodeficiency virus Tat and Rev proteins. Trends Biochem. Sci. 1993, 18, 255-259.
153. Gatignol, A.; Duarte, M.; Daviet, L.; Chang, Y. N.; Jeang, K. T. Sequential steps in Tat trans-activation of HIV-1 mediated through cellular DNA, RNA, and protein binding factors. Gene Expr. 1996, 5, 217-228.
154. Zimmermann, B.; Bilusic, I.; Lorenz, C.; Schroeder, R. Genomic SELEX: A discovery tool for genomic aptamers. Methods 2010, 52, 125-132.
155. Li, M.; Rossi, J. J. Lentiviral vector delivery of siRNA and shRNA encoding genes into cultured and primary hematopoietic cells. Methods Mol. Biol. 2005, 309, 261-272.
156. DiGiusto, D. L.; Krishnan, A.; Li, L.; Li, H.; Li, S.; Rao, A.; Mi, S.; Yam, P.; Stinson, S.; Kalos, M.; et al. RNA-based gene therapy for HIV with lentiviral vector-modified CD34(+) cells in patients undergoing transplantation for AIDS-related lymphoma. Sci. Transl. Med. 2010, 2, 36ra43.
157. Wasley, A.; Alter, M. J. Epidemiology of hepatitis C: Geographic differences and temporal trends. Semin. Liver Dis. 2000, 20, 1-16.
158. Hanazaki, K. Antiviral therapy for chronic hepatitis B: A review. Curr. Drug Targets Inflamm. Allergy 2004, 3, 63-70.
159. Kato, N. Genome of human hepatitis C virus (HCV): Gene organization, sequence diversity, and variation. Microb. Comp. Genomics 2000, 5, 129-151.
160. Failla, C.; Tomei, L.; de Francesco, R. Both NS3 and NS4A are required for proteolytic processing of hepatitis C virus nonstructural proteins. J. Virol. 1994, 68, 3753-3760.
161. Kim, D. W.; Gwack, Y.; Han, J. H.; Choe, J. C-terminal domain of the hepatitis C virus NS3 protein contains an RNA helicase activity. Biochem. Biophys. Res. Commun. 1995, 215, 160-166.
162. Nishikawa, F.; Kakiuchi, N.; Funaji, K.; Fukuda, K.; Sekiya, S.; Nishikawa, S. Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res. 2003, 31, 1935-1943.
163. Fukuda, K.; Umehara, T.; Sekiya, S.; Kunio, K.; Hasegawa, T.; Nishikawa, S. An RNA ligand inhibits hepatitis C virus NS3 protease and helicase activities. Biochem. Biophys. Res. Commun. 2004, 325, 670-675.
164. Umehara, T.; Fukuda, K.; Nishikawa, F.; Kohara, M.; Hasegawa, T.; Nishikawa, S. Rational design of dual-functional aptamers that inhibit the protease and helicase activities of HCV NS3. J. Biochem. 2005, 137, 339-347.
165. Varshney, J.; Sharma, P. K.; Sharma, A. A review on an update of NS5B polymerase hepatitis C virus inhibitors. Eur. Rev. Med. Pharmacol. Sci. 2012, 16, 667-671.
166. Tsukiyama-Kohara, K.; Iizuka, N.; Kohara, M.; Nomoto, A. Internal ribosome entry site within hepatitis C virus RNA. J. Virol. 1992, 66, 1476-1483.
167. Gallego, J.; Varani, G. The hepatitis C virus internal ribosome-entry site: A new target for antiviral research. Biochem. Soc. Trans. 2002, 30, 140-145.
168. Kikuchi, K.; Umehara, T.; Nishikawa, F.; Fukuda, K.; Hasegawa, T.; Nishikawa, S. Increased inhibitory ability of conjugated RNA aptamers against the HCV IRES. Biochem. Biophys. Res. Commun. 2009, 386, 118-123.
169. Chen, Y.; Cheng, G.; Mahato, R. I. RNAi for treating hepatitis B viral infection. Pharm. Res. 2008, 25, 72-86.
170. Zoulim, F. Hepatitis B virus resistance to antiviral drugs: Where are we going? Liver Int. 2011, 31, 111-116.
171. Seeger, C.; Mason, W. S. Hepatitis B virus biology. Microbiol. Mol. Biol. Rev. 2000, 64, 51-68.
172. Summers, J.; Mason, W. S. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982, 29, 403-415.
173. Wang, G. H.; Seeger, C. The reverse transcriptase of hepatitis B virus acts as a protein primer for viral DNA synthesis. Cell 1992, 71, 663-670.
174. Hirsch, R. C.; Lavine, J. E.; Chang, L. J.; Varmus, H. E.; Ganem, D. Polymerase gene products of hepatitis B viruses are required for genomic RNA packaging as wel as for reverse transcription. Nature 1990, 344, 552-555.
175. Flodell, S.; Petersen, M.; Girard, F.; Zdunek, J.; Kidd-Ljunggren, K.; Schleucher, J.; Wijmenga, S. Solution structure of the apical stem-loop of the human hepatitis B virus encapsidation signal. Nucleic Acids Res. 2006, 34, 4449-4457.
176. Peiris, J. S.; Lai, S. T.; Poon, L. L.; Guan, Y.; Yam, L. Y.; Lim, W.; Nicholls, J.; Yee, W. K.; Yan, W. W.; Cheung, M. T.; et al. Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003, 361, 1319-1325.
177. Stadler, K.; Masignani, V.; Eickmann, M.; Becker, S.; Abrignani, S.; Klenk, H. D.; Rappuoli, R. SARS-beginning to understand a new virus. Nat. Rev. Microbiol. 2003, 1, 209-218.
178. Tanner, J. A.; Watt, R. M.; Chai, Y. B.; Lu, L. Y.; Lin, M. C.; Peiris, J. S.; Poon, L. L.; Kung, H. F.; Huang, J. D. The severe acute respiratory syndrome (SARS) coronavirus NTPase/helicase belongs to a distinct class of 5' to 3' viral helicases. J. Biol. Chem. 2003, 278, 39578-39582.
179. Zaki, A. M.; van Boheemen, S.; Bestebroer, T. M.; Osterhaus, A. D.; Fouchier, R. A. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N. Engl. J. Med. 2012, 367, 1814-1820.
180. Van Boheemen, S.; de Graaf, M.; Lauber, C.; Bestebroer, T. M.; Raj, V. S.; Zaki, A. M.; Osterhaus, A. D.; Haagmans, B. L.; Gorbalenya, A. E.; Snijder, E. J.; et al. Genomic characterization of a newly discovered coronavirus associated with acute respiratory distress syndrome in humans. mBio 2012, doi: 10. 1128/mBio. 00473-12.
181. Josset, L.; Menachery, V. D.; Gralinski, L. E.; Agnihothram, S.; Sova, P.; Carter, V. S.; Yount, B. L.; Graham, R. L.; Baric, R. S.; Katze, M. G. Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. mBio 2013, doi: 10. 1128/mBio. 00165-13.
182. Elderfield, R.; Barclay, W. Influenza pandemics. Adv. Exp. Med. Biol. 2011, 719, 81-103.
183. Webster, R. G. 1918 Spanish influenza: The secrets remain elusive. Proc. Natl. Acad. Sci. USA 1999, 96, 1164-1166.
184. Bai, T.; Zhou, J.; Shu, Y. Serologic study for influenza A (H7N9) among high-risk groups in China. N. Engl. J. Med. 2013, 368, 2339-2340.
185. Watanabe, Y.; Ibrahim, M. S.; Suzuki, Y.; Ikuta, K. The changing nature of avian influenza A virus (H5N1). Trends Microbiol. 2012, 20, 11-20.
186. Gultyaev, A. P.; Fouchier, R. A.; Olsthoorn, R. C. Influenza virus RNA structure: Unique and common features. Int. Rev. Immunol. 2010, 29, 533-556.
187. Saladino, R.; Barontini, M.; Crucianelli, M.; Nencioni, L.; Sgarbanti, R.; Palamara, A. T. Current advances in anti-influenza therapy. Curr. Med. Chem. 2010, 17, 2101-2140.
188. Stropkovska, A.; Janulikova, J.; Vareckova, E. Trends in development of the influenza vaccine with broader cross-protection. Acta Virol. 2010, 54, 7-19.
189. Burton, D. R.; Poignard, P.; Stanfield, R. L.; Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 2012, 337, 183-186.
190. Skehel, J. J.; Wiley, D. C. Receptor binding and membrane fusion in virus entry: The influenza hemagglutinin. Annu. Rev. Biochem. 2000, 69, 531-569.
191. Nicholson, K. G.; Wood, J. M.; Zambon, M. Influenza. Lancet 2003, 362, 1733-1745.
192. Yousaf, M. Z.; Qasim, M.; Zia, S.; Khan, M.; Ashfaq, U. A.; Khan, S. Rabies molecular virology, diagnosis, prevention and treatment. Virol. J. 2012, 9, 50.
193. Dietzschold, B.; Schnell, M.; Koprowski, H. Pathogenesis of rabies. Curr. Top. Microbiol. Immunol. 2005, 292, 45-56.
194. Stanley, M. Pathology and epidemiology of HPV infection in females. Gynecol. Oncol. 2010, 117, S5-S10.
195. McLaughlin-Drubin, M. E.; Meyers, J.; Munger, K. Cancer associated human papillomaviruses. Curr. Opin. Virol. 2012, 2, 459-466.
196. Wilczynski, S. P.; Bergen, S.; Walker, J.; Liao, S. Y.; Pearlman, L. F. Human papillomaviruses and cervical cancer: Analysis of histopathologic features associated with different viral types. Hum. Pathol. 1988, 19, 697-704.
197. Thomas, M.; Narayan, N.; Pim, D.; Tomaic, V.; Massimi, P.; Nagasaka, K.; Kranjec, C.; Gammoh, N.; Banks, L. Human papillomaviruses, cervical cancer and cell polarity. Oncogene 2008, 27, 7018-7030.
198. DiMaio, D.; Liao, J. B. Human papillomaviruses and cervical cancer. Adv. Virus Res. 2006, 66, 125-159.
199. Mineta, H.; Ogino, T.; Amano, H. M.; Ohkawa, Y.; Araki, K.; Takebayashi, S.; Miura, K. Human papilloma virus (HPV) type 16 and 18 detected in head and neck squamous cell carcinoma. Anticancer Res. 1998, 18, 4765-4768.
200. Schiller, J. T.; Lowy, D. R. Understanding and learning from the success of prophylactic human papillomavirus vaccines. Nat. Rev. Microbiol. 2012, 10, 681-692.
201. Ghittoni, R.; Accardi, R.; Hasan, U.; Gheit, T.; Sylla, B.; Tommasino, M. The biological properties of E6 and E7 oncoproteins from human papillomaviruses. Virus Genes 2010, 40, 1-13.
202. Nauenburg, S.; Zwerschke, W.; Jansen-Durr, P. Induction of apoptosis in cervical carcinoma cells by peptide aptamers that bind to the HPV-16 E7 oncoprotein. FASEB J. 2001, 15, 592-594.
203. Finzer, P.; Aguilar-Lemarroy, A.; Rosl, F. The role of human papillomavirus oncoproteins E6 and E7 in apoptosis. Cancer Lett. 2002, 188, 15-24.
204. Maldonado, E.; Cabrejos, M. E.; Banks, L.; Allende, J. E. Human papillomavirus-16 E7 protein inhibits the DNA interaction of the TATA binding transcription factor. J. Cell. Biochem. 2002, 85, 663-669.
205. Bernat, A.; Avvakumov, N.; Mymryk, J. S.; Banks, L. Interaction between the HPV E7 oncoprotein and the transcriptional coactivator p300. Oncogene 2003, 22, 7871-7881.
206. Draper, K. G.; Frink, R. J.; Devi, G. B.; Swain, M.; Galloway, D.; Wagner, E. K. Herpes simplex virus types 1 and 2 homology in the region between 0. 58 and 0. 68 map units. J. Virol. 1984, 52, 615-623.
207. Rozenberg, F.; Deback, C.; Agut, H. Herpes simplex encephalitis: From virus to therapy. Infect. Disord. Drug Targets 2011, 11, 235-250.
208. Reske, A.; Pollara, G.; Krummenacher, C.; Chain, B. M.; Katz, D. R. Understanding HSV-1 entry glycoproteins. Rev. Med. Virol. 2007, 17, 205-215.
209. Lasky, L. A.; Dowbenko, D. J. DNA sequence analysis of the type-common glycoprotein-D genes of herpes simplex virus types 1 and 2. DNA 1984, 3, 23-29.
210. Zhou, J.; Shum, K. T.; Burnett, J. C.; Rossi, J. J. Nanoparticle-based delivery of RNAi therapeutics: Progress and challenges. Pharmaceuticals 2013, 6, 85-107.
211. James, W. Aptamers in the virologists' toolkit. J. Gen. Virol. 2007, 88, 351-364.
212. Moore, M. D.; Cookson, J.; Coventry, V. K.; Sproat, B.; Rabe, L.; Cranston, R. D.; McGowan, I.; James, W. Protection of HIV neutralizing aptamers against rectal and vaginal nucleases: Implications for RNA-based therapeutics. J. Biol. Chem. 2011, 286, 2526-2535.
213. Wheeler, L. A.; Vrbanac, V.; Trifonova, R.; Brehm, M. A.; Gilboa-Geffen, A.; Tanno, S.; Greiner, D. L.; Luster, A. D.; Tager, A. M.; Lieberman, J. Durable knockdown and protection from HIV transmission in humanized mice treated with gel-formulated CD4 aptamer-siRNA chimeras. Mol. Ther. 2013, 21, 1378-1389.